Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ProQR ( (PRQR) ) has issued an announcement.
On November 3, 2025, ProQR Therapeutics hosted a virtual analyst and investor event to discuss its lead pipeline program, AX-0810, which is entering a first-in-human clinical trial targeting NTCP in cholestatic diseases. The event highlighted the company’s strategic overview and corporate outlook, emphasizing the establishment of safety, pharmacokinetics, and a biomarker roadmap for proof of target engagement. This development positions ProQR at the forefront of RNA editing medicines, particularly in neurological applications, and underscores its commitment to addressing unmet medical needs in various diseases.
The most recent analyst rating on (PRQR) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on ProQR stock, see the PRQR Stock Forecast page.
Spark’s Take on PRQR Stock
According to Spark, TipRanks’ AI Analyst, PRQR is a Neutral.
ProQR’s stock score is primarily impacted by its financial performance challenges, including declining revenue and persistent losses. While technical analysis shows bullish momentum, the negative valuation metrics, such as the P/E ratio, weigh heavily on the overall score. The absence of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on PRQR stock, click here.
More about ProQR
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands, specializing in RNA editing technologies. The company focuses on developing therapies for genetic disorders, with a significant emphasis on its Axiomer RNA editing platform. ProQR has established strategic partnerships, including a notable collaboration with Eli Lilly, to advance its pipeline of treatments targeting a range of high unmet medical needs, such as cholestatic diseases, Rett syndrome, and cardiovascular diseases.
Average Trading Volume: 455,394
Technical Sentiment Signal: Buy
Current Market Cap: $289.3M
See more insights into PRQR stock on TipRanks’ Stock Analysis page.